MRI for men undergoing active surveillance or with rising PSA and negative biopsies

Nature Reviews Urology

Volumn 7, Issue 10, 2010, Pages 543-551

  Raz, Orit ^a   Haider, Masoom ^b   Trachtenberg, John ^a   Leibovici, Dan ^c   Lawrentschuk, Nathan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c ASSAF HAROFEH MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; FOLLOW UP; HUMAN; IMAGING SYSTEM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; THREE DIMENSIONAL IMAGING; WHOLE BODY MRI;

BIOPSY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77958048690     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2010.143     Document Type: Review

References (73)

1. Biondetti, P. R., Lee, J. K., Ling, D. & Catalona, w. J. Clinical stage B prostate carcinoma: Staging with MR imaging. Radiology 162, 325-329 (1987). (Pubitemid 17015631)
2. Bockisch, A. et al. Magnetic resonance (MR) imaging of prostatic tumours, a comparison with X-ray CT and transrectal sonography (TRS). Eur. J. Radiol. 8, 54-149 (1988).
3. Steyn, J. H. & Smith, F. W. Nuclear magnetic resonance (NMR) imaging of the prostate. Br. J. Urol. 56, 679-681 (1984).
4. weinreb, J. C. et al. Prostate cancer: Sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy-results of ACRIN prospective multi-institutional clinicopathologic study. Radiology 251, 122-133 (2009).
5. Gofrit, O. N., Zorn, K. C., Steinberg, G. D., Zagaja, G. P. & Shalhav, A. L. The will Rogers phenomenon in urological oncology. J. Urol. 179, 28-33 (2008).
6. Kirkham, A. P., emberton, M. & Allen, C. How good is MRI at detecting and characterising cancer within the prostate? Eur. Urol. 50, 1163-1174 (2006).
7. Augustin, H., Fritz, G. A., ehammer, T., Auprich, M. & Pummer, K. Accuracy of 3-Tesla magnetic resonance imaging for the staging of prostate cancer in comparison to the Partin tables. Acta Radiol. 50, 562-569 (2009).
8. Fütterer, J. J. et al. Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate. Invest. Radiol. 39, 671-680 (2004).
9. The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Prostate Cancer-v.3.2010 [online], http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp (2010).
10. Shukla-Dave, A., Hricak, H. & Scardino, P. T. Imaging low-risk prostate cancer. Curr. Opin. Urol. 18, 78-86 (2008).
11. Mullerad, M. et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J. Urol. 174, 2158-2163 (2005).
12. Turkbey, B. et al. Prostate cancer: Value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 255, 89-99 (2010).
13. Kurhanewicz, J., vigneron, D., Carroll, P. & Coakley, F. Multiparametric magnetic resonance imaging in prostate cancer: Present and future. Curr. Opin. Urol. 18, 71-77 (2008).
14. Lindner, U. et al. Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J. Urol. 182, 1371-1377 (2009).
15. Scheidler, J. et al. Prostate cancer: Localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213, 473-480 (1999). (Pubitemid 29510595)
16. Nogueira, L. et al. Focal treatment or observation of prostate cancer: Pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI. Urology 75, 472-477 (2009).
17. Mullerad, M. et al. Prostate cancer: Detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 232, 140-146 (2004).
18. wang, L. et al. Prostate cancer: Incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232, 133-139 (2004).
19. wang, L. et al. Prediction of organ-confined prostate cancer: Incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 238, 597-603 (2006).
20. Dhingsa, R. et al. Prostate cancer localization with endorectal MR imaging and MR spectroscopic imaging: Effect of clinical data on reader accuracy. Radiology 230, 215-220 (2004).
21. Casciani, e. et al. Prostate cancer: Evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiol. Med. 108, 530-541 (2004).
22. Fütterer, J. J. et al. Prostate cancer: Local staging at 3-T endorectal MR imaging-early experience. Radiology 238, 184-191 (2006).
23. Miao, H., Fukatsu, H. & Ishigaki, T. Prostate cancer detection with 3-T MRI: Comparison of diffusion-weighted and T2-weighted imaging. Eur. J. Radiol. 61, 297-302 (2007).
24. Girouin, N. et al. Prostate dynamic contrastenhanced MRI with simple visual diagnostic criteria: Is it reasonable? Eur. Radiol. 17, 1498-1509 (2007).
25. Hara, N., Okuizumi, M., Koike, H., Kawaguchi, M. & Bilim, v. Dynamic contrast-enhanced magnetic resonance imaging (DCe-MRI) is a useful modality for the precise detection and staging of early prostate cancer. Prostate 62, 140-147 (2005).
26. Ito, H., Kamoi, K., Yokoyama, K., Yamada, K. & Nishimura, T. visualization of prostate cancer using dynamic contrast-enhanced MRI: Comparison with transrectal power Doppler ultrasound. Br. J. Radiol. 76, 617-624 (2003).
27. Heijmink, S. W. et al. Prostate cancer: Body-array versus endorectal coil MR imaging at 3 T-comparison of image quality, localization, and staging performance. Radiology 244, 184-195 (2007).
28. Zakian, K. L. et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 234, 804-814 (2005).
29. Tofts, P. S. et al. estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J. Magn. Reson. Imaging 10, 223-232 (1999).
30. Furman-Haran, e., Margalit, R., Grobgeld, D. & Degani, H. Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors. Proc. Natl Acad. Sci. USA 93, 6247-6251 (1996).
31. Choyke, P. L., Dwyer, A. J. & Knopp, M. V. Functional tumor imaging with dynamic contrastenhanced magnetic resonance imaging. J. Magn. Reson. Imaging 17, 509-520 (2003).
32. Brix, G. et al. Pharmacokinetic parameters in CNS Gd-DTPA enhanced MR imaging. J. Comput. Assist. Tomogr. 15, 621-628 (1991).
33. wefer, A. E. et al. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J. Urol. 164, 400-404 (2000).
34. Shukla-Dave, A. et al. The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: An initial analysis. BJU Int. 99, 786-793 (2007).
35. Poulakis, v. et al. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy. Urology 64, 1165-1170 (2004). (Pubitemid 39647060)
36. Kozlowski, P. et al. Combined diffusion-weighted and dynamic contrast-enhanced MRI for prostate cancer diagnosis-correlation with biopsy and histopathology. J. Magn. Reson. Imaging 24, 108-113 (2006).
37. Issa, B. In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J. Magn. Reson. Imaging 16, 196-200 (2002).
38. Hosseinzadeh, K. & Schwarz, S. D. endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J. Magn. Reson. Imaging 20, 654-661 (2004).
39. Mazaheri, Y. et al. Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: Correlation with pathologic tumor volume. Radiology 252, 449-457 (2009).
40. Haider, M. A. et al. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am. J. Roentgenol. 189, 323-328 (2007).
41. Gibbs, P., Tozer, D. J., Liney, G. P. & Turnbull, L. W. Comparison of quantitative T2 mapping and diffusion-weighted imaging in the normal and pathologic prostate. Magn. Reson. Med. 46, 1054-1058 (2001).
42. Noworolski, S. M., vigneron, D. B., Chen, A. P. & Kurhanewicz, J. Dynamic contrast-enhanced MRI and MR diffusion imaging to distinguish between glandular and stromal prostatic tissues. Magn. Reson. Imaging 26, 1071-1080 (2008).
43. Concato, J. et al. Molecular markers and mortality in prostate cancer. BJU Int. 100, 1259-1263 (2007).
44. Schmuecking, M. et al. Dynamic MRI and CAD vs. choline MRS: Where is the detection level for a lesion characterisation in prostate cancer? Int. J. Radiat. Biol. 85, 814-824 (2009).
45. Kim, C. K., Park, B. K. & Kim, B. Localization of prostate cancer using 3T MRI: Comparison of T2-weighted and dynamic contrast-enhanced imaging. J. Comput. Assist. Tomogr. 30, 7-11 (2006).
46. Ocak, I. et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: A study of pharmacokinetic parameters. AJR Am. J. Roentgenol. 189, 849 (2007).
47. Jackson, A. S. et al. Dynamic contrast-enhanced MRI for prostate cancer localization. Br. J. Radiol. 82, 148-156 (2009).
48. Zelhof, B., Lowry, M., Rodrigues, G., Kraus, S. & Turnbull, L. Description of magnetic resonance imaging-derived enhancement variables in pathologically confirmed prostate cancer and normal peripheral zone regions. BJU Int. 104, 621-627 (2009).
49. Yakar, D. et al. Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy. Invest. Radiol. 45, 121-125 (2010).
50. Tokuda, J. et al. Integrated navigation and control software system for MRI-guided robotic prostate interventions. Comput. Med. Imaging Graph. 34, 3-8 (2010).
51. Yakar, D., Hambrock, T., Hoeks, C., Barentsz, J. O. & Fütterer, J. J. Magnetic resonance-guided biopsy of the prostate: Feasibility, technique, and clinical applications. Top. Magn. Reson. Imaging 19, 291-295 (2008).
52. Tarone, R. e., Chu, K. C. & Brawley, O. W. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology 11, 167-170 (2000).
53. Hussain, S. et al. Secular trends in prostate cancer mortality, incidence and treatment: England and wales, 1975-2004. BJU Int. 101, 547-555 (2008).
54. Collin, S. M. et al. Prostate-cancer mortality in the USA and UK in 1975-2004: An ecological study. Lancet Oncol. 9, 445-452 (2008).
55. Hankey, B. F. et al. Cancer surveillance series: Interpreting trends in prostate cancer-part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J. Natl Cancer Inst. 91, 1017-1024 (1999).
56. Rohde, v., weidner, w. & Katalinic, A. Decrease in prostate cancer incidence and mortality in Germany-effects of opportunistic PSA screening or more? Urol. Int. 83, 134-140 (2009).
57. Chu, K. C., Tarone, R. E. & Freeman, H. P. Trends in prostate cancer mortality among black men and white men in the United States. Cancer 97, 1507-1516 (2003).
58. Choo, R. et al. Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J. Urol. 167, 1664-1669 (2002).
59. Ploussard, G. et al. The role of biopsy core number in selecting prostate cancer patients for active surveillance. Eur. Urol. 56, 891-898 (2009).
60. Barocas, D. A., Cowan, J. e., Smith, J. A. Jr & Carroll, P. R. what percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURe database. J. Urol. 180, 1330-1334 (2008).
61. Lawrentschuk, N. et al. 'Prostatic evasive anterior tumours': The role of magnetic resonance imaging. BJU Int. 105, 1231-1236 (2010).
62. Bastian, P. J. et al. Insignificant prostate cancer and active surveillance: From definition to clinical implications. Eur. Urol. 55, 1321-1330 (2009).
63. Cabrera, A. R. et al. Prostate cancer: Is inapparent tumor at endorectal MR and MR spectroscopic imaging a favorable prognostic finding in patients who select active surveillance? Radiology 247, 444-450 (2008).
64. van As, N. J. et al. A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur. Urol. 56, 981-988 (2008).
65. deSouza, N. M. et al. Diffusion-weighted magnetic resonance imaging: A potential noninvasive marker of tumour aggressiveness in localized prostate cancer. Clin. Radiol. 63, 774-782 (2008).
66. Franiel, T. et al. Pharmacokinetic MRI of the prostate: Parameters for differentiating lowgrade and high-grade prostate cancer [German]. Rofo 181, 536-542 (2009).
67. Hambrock, T. et al. Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. J. Urol. 183, 520-527 (2009).
68. Beyersdorff, D. et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: Value of MR imaging. Radiology 224, 701-706 (2002).
69. Cirillo, S. et al. value of endorectal MRI and MRS in patients with elevated prostate-specific antigen levels and previous negative biopsies to localize peripheral zone tumours. Clin. Radiol. 63, 871-879 (2008).
70. Perrotti, M. et al. Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostastic biopsy: A pilot study. J. Urol. 162, 1314-1317 (1999).
71. villeirs, G. M. et al. Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: A single-institution experience of 356 patients. Eur. J. Radiol. doi:10.1016/j.ejrad.2009.08.007.
72. Yuen, J. S. et al. endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J. Urol. 171, 1482-1486 (2004).
73. Prando, A., Kurhanewicz, J., Borges, A. P., Oliveira, e. M. Jr & Figueiredo, e. Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: Early experience. Radiology 236, 903-910 (2005). (Pubitemid 41170854)